| Document |
Document Title |
|
WO/2011/125836A1 |
Disclosed is a therapeutic agent or prophylactic agent that has analgesic effects on both nociceptive pain and neuropathic pain and is effective in the treatment of fibromyalgia. Specifically disclosed is a therapeutic agent or prophylac...
|
|
WO/2011/123674A1 |
The invention provides novel spirotetrahydronaphthalene compounds of Formula α that inhibit β-secretase cleavage of APP and are useful as therapeutic agents for treating neurodegenerative diseases.
|
|
WO/2011/120604A1 |
The invention discloses compounds of formula I wherein Y is a group of formula A, B, C, D, or E: and W, Q, n, R1, R2, R3, U1-U5, J and K have the meanings given in the description. The compounds of formula I are TRPV1 antagonists and are...
|
|
WO/2011/118672A1 |
Disclosed is a pharmaceutical product, particularly a pharmaceutical composition having a plasma kallikrein inhibition activity and is useful as a prophylactic or therapeutic agent for edemas (particularly hereditary vascular edema and c...
|
|
WO/2011/114210A2 |
Disclosed herein a process for preparing linezolid, wherein the resultant linezolide is devoid of impurities and involve easy and economical process. The present invention further relates to preparation of linezolid by employing an azide...
|
|
WO/2011/094890A1 |
Provided herein are non-peptide GLP-1 receptor modulator compounds, for example, of Formula (I), pharmaceutical compositions comprising such compounds, and processes of preparation thereof. Also provided are methods of their use for the ...
|
|
WO/2011/096462A1 |
Provided is a compound represented by formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof as a novel compound having an NPY Y5 receptor antagonistic activity. In formula (I), R1, R2, and R3 each independently re...
|
|
WO/2011/095338A1 |
The present invention relates to novel aminoalkyl-oxazole and aminoalkyl-thiazole carboxylic acid amides that stimulate the endogenous regeneration of terminally differentiated cells in highly specialized organs, tissues and sensory epit...
|
|
WO/2011/097260A1 |
Compounds represented by Formula (1) are described herein. Light-emitting devices containing the compound of Formula (1) are also described herein. Wherein Ph1 is optionally substituted phenyl; Ar1, Ar2, and Ar3 are independently optiona...
|
|
WO/2011/092611A1 |
Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, met...
|
|
WO/2011/086561A1 |
The present invention relates to a process for the preparation of highly pure 3-(1-cyclopropenyl) propionic acid salt, particulary 3-(1-cyclopropenyl) propionic acid sodium salt, an ethylene receptor antagonist that may be used for inhib...
|
|
WO/2011/088015A1 |
Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are ...
|
|
WO/2011/082732A1 |
The invention relates to compounds of formula (I), where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, M1, M2, M3, M4, Y1, Y2, V, W, n, m and o have the meanings specified herein, and to the physiologically ...
|
|
WO/2011/082077A1 |
The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such compound...
|
|
WO/2011/077252A2 |
The invention relates to improvements of the physiochemical and/or the pharmaceutical properties of metaxalone. Disclosed herein are several new cocrystals of metaxalone, including: a 1:1 metaxalore adipic acid cocrystal, a 1:0.5 metaxal...
|
|
WO/2011/077310A1 |
The present invention provides an improved process for the preparation of Linezolid of formula (D. The present invention relates to preparation of intermediate (R)-N-[[3-[3-fluoro-4-morpholinyl] phenyl |-2-oxo-5-oxazolidinyl] methanol of...
|
|
WO/2011/075631A1 |
The present invention is directed to substituted benzothiazole and benzoxazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by DPP-1.
|
|
WO/2011/070177A2 |
Disclosed are compounds and methods for treating neurological and other disorders by administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for GFRα receptor molecules, ...
|
|
WO/2011/070030A1 |
The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The compounds have been demonstrated as inhibitors of MEK and therefore may be useful in the treatment of hyperproliferative disease...
|
|
WO/2011/067538A1 |
The invention relates to a method for preparing a combretastatin derivative (I) or (II), said method including the following steps: triaryl(3,4,5-trimethoxybenzyl)phosphonium halide P3 (III), wherein Ar denotes an aryl group selected fro...
|
|
WO/2011/065351A1 |
Disclosed is a method for producing a compound represented by formula (I) (wherein R1s, R3, n and X are as defined in formula (IV) or formula (V) below with respect to the same symbols), a salt thereof or a solvate of the compound or sal...
|
|
WO/2011/066184A1 |
The present invention relates to novel amine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1 -phosphate receptors.
|
|
WO/2011/059042A1 |
Disclosed is a compound represented by formula (I) (wherein the symbols are as defined in the description) or a salt thereof, which exhibits excellent long chain fatty acid elongase 6 inhibitory activity and is useful for prevention and ...
|
|
WO/2011/056645A2 |
A process of the present invention is directed toward conducting highly selective, high yield post-polymerization reactions on polypeptides to prepare functionalized polypeptides. In certain embodiments, the polypeptides can be prepared ...
|
|
WO/2011/055289A2 |
The present invention relates to novel heteroaryl compounds, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or disorders mediated by Diacylglycerol acyltransferase ...
|
|
WO/2011/054292A1 |
At least one crystalline hydrate of (S)-[N-3-(3'-fluoro-4'-(4''-phenyl piperazinyl)) phenyl-2-oxo-5-oxazolidinyl] methyl acetamide, such as those with the following formula, wherein y is a number ranging from 1/12 to 1. Also provided are...
|
|
WO/2011/056126A1 |
The present invention relates to certain novel 1,3-oxazolidine compounds of formula (I), to processes for making such compounds and to their utility as renin inhibitors or prodrugs of renin inhibitors.
|
|
WO/2011/051384A1 |
The invention relates to a process for making a crystalline linezolid, comprising a step of dissolving linezolid in an organic solvent to obtain a solution followed by a step of adding the obtained solution into an antisolvent kept at a ...
|
|
WO/2011/050865A1 |
The invention relates to a process for making a crystalline linezolid, comprising a step of dissolving linezolid in an organic solvent to obtain a solution followed by a step of adding the obtained solution into an antisolvent kept at a ...
|
|
WO/2005/060456A9 |
The present invention relates to methods of treating ADAMTS-S-associated diseases and particularly osteoarthritis comprising administering an agent capable an of modulating ADMATS-5 activity to a subject afflicted with the disease. The a...
|
|
WO/2011/050826A1 |
The invention relates to a process for making a crystalline linezolid, comprising a step of dissolving linezolid in an organic solvent to obtain a solution followed by a step of adding the obtained solution into an antisolvent kept at a ...
|
|
WO/2011/051455A1 |
The present invention relates to novel pesticidal azolidine derivatives as well as to oxazolidinone derivatives and their use as pesticides for combating animal parasites which occur in the agrochemical field and in the field of veterina...
|
|
WO/2011/051191A1 |
The present invention relates to non-crystallising oxazolidines as curing agents for polyisocyanates, respectively polyurethanes. These curing agents are essentially mixtures of at least one polyoxazolidine POU having at least two uretha...
|
|
WO/2011/047432A1 |
The present invention relates to arylcarbonyl and heteroarylcarbonyl anthranilate compounds that may be useful as anti-fibrotic agents. The present invention also relates to methods for their preparation, pharmaceutical compositions cont...
|
|
WO/2011/048018A1 |
The invention relates to cyclopentanecarboxamide derivatives of formula 1, to their use as Fatty Acid Synthase inhibitors, to methods for their therapeutic use and to pharmaceutical compositions containing them, wherein R1, R2, R3, LO, W...
|
|
WO/2011/047390A2 |
This invention relates to benzoxazole compounds, compositions and devices for delivering them, processes for manufacturing them, and methods of using them in the treatment of Hepatitis C Virus.
|
|
WO/2011/044978A1 |
The invention relates to sulfoxide derivatives of the formula Ia to Im as described and to the pharmaceutically usable salts, solvates, enantiomers, tautomers, and stereoisomers thereof, including mixtures thereof in all ratios for treat...
|
|
WO/2011/046954A1 |
The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseas...
|
|
WO/2011/044506A2 |
The invention provides sulphone compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various sulphone compounds are provided. The compounds are contemplated to have act...
|
|
WO/2011/035569A1 |
A novel process, novel process steps and novel intermediates useful in the synthesis of pharmaceutically active compounds, in particular neutral endopeptidase (NEP) inhibitors.
|
|
WO/2011/037192A1 |
Disclosed is a substituted amide represented by formula (I), which is useful as an active ingredient of a pharmaceutical composition, especially as an active ingredient of a pharmaceutical composition for the treatment of diseases that a...
|
|
WO/2011/037223A1 |
Disclosed is an FGF21 production enhancer which contains a compound represented by general formula (1), a salt thereof or a solvate of the compound or salt as an active ingredient. (In the formula, R1 and R2 may be the same or different ...
|
|
WO/2011/030927A1 |
Use of a compound represented by formula (I), a salt of the compound, or a solvate of the compound or the salt for inhibiting type-3 17β-hydroxysteroid dehydrogenase; and others.
|
|
WO/2011/029460A1 |
The present invention relates to an acid addition salt of linezolid with naphthalene- 1,5-disulfonic acid or with p-toluene sulfonic acid such as linezolid mono-naphtalene-1,5- disulfonate (linezolid hydrogennapadisylate), linezolid hemi...
|
|
WO/2011/030591A1 |
Disclosed is a novel zinc cluster compound represented by general formula (1): Zn4O(OCOR)6(RCOOH)n, wherein R represents an alkyl group which has 1 to 4 carbon atoms and may be substituted with a halogen atom, and n represents 0.1 to 1, ...
|
|
WO/2011/026781A1 |
The invention relates to compounds of the general formula (1) or the acid addition salts thereof with organic and/or inorganic acids; as well as to the use of the compounds of the general formula (1) in medicine.
|
|
WO/2011/025545A1 |
Provided are novel compositions and analogs which are useful in a number of applications, indications and diseases, as well as for monitoring pharmakinetics and patient management. These compounds and analogs are applicable to treating t...
|
|
WO/2011/024986A1 |
To provide an organic electroluminescence device having high luminous efficiency (for example, external quantum efficiency) and high durability and causing little chromaticity shift after device deterioration. An organic electroluminesce...
|
|
WO/2011/017907A1 |
Preparation of azetidinone compounds and medical use thereof are provided by the present invention. More particularly, azetidinone compounds, shown as formula (I), wherein R1, R2, R3, R4, R5, R6 are defined in description, and preparatio...
|
|
WO/2011/014332A1 |
Described herein are compounds useful as agonists of alpha 2B/2C receptors. Pharmaceutical compositions including the presently described compounds and methods of treatment of diseases and conditions with the presently described compound...
|
